Triptorelin
Also referenced as: Trelstar, Triptodur
A GnRH agonist used for product-specific endocrine suppression.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Trelstar is FDA-approved for advanced prostate cancer; Triptodur treats central precocious puberty in children aged 2 and older.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH agonist used for product-specific endocrine suppression.
Trelstar is FDA-approved for advanced prostate cancer; Triptodur treats central precocious puberty in children aged 2 and older.
Cancer and pediatric formulations are not interchangeable, and hormonal suppression is not general sexual-health optimization.
Why It's Being Studied
- Advanced prostate cancer
- Central precocious puberty
Mechanism of Action
Chronic receptor activation reduces gonadal steroid production after an initial stimulation phase.
Chronic receptor activation reduces gonadal steroid production after an initial stimulation phase. Cancer and pediatric formulations are not interchangeable, and hormonal suppression is not general sexual-health optimization.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Advanced prostate cancer
- Central precocious puberty
- Product-specific approved depot injections
Evidence Summary
Clinical evidence supports advanced prostate-cancer and central precocious-puberty indications.
Higher tiers carry more weight. Filled tiers have evidence for Triptorelin; tap to read it.
- Clinical evidence supports advanced prostate-cancer and central precocious-puberty indications.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical evidence supports advanced prostate-cancer and central precocious-puberty indications.
Reported Adverse Events in Research
- Initial flare, bone and metabolic effects, pediatric psychiatric or seizure warnings and intracranial-hypertension precautions are relevant.
Limitations of Current Evidence
- Cancer and pediatric formulations are not interchangeable, and hormonal suppression is not general sexual-health optimization.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Triptorelin | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Product-specific approved depot injections | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Triptorelin — prescribing label